What question did this study set out to answer?

The study aims to evaluate the efficacy of a regimen combining cladribine, cytarabine, and venetoclax in older or unfit patients with newly diagnosed acute myeloid leukemia.

April 27, 2026American Journal of Hematology

Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

View Full Paper

Ask AI

Bookmark

Authors

TKTapan M. Kadia ABAlex Bataller ABAlexandre BazinetThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Phase II study evaluates cladribine and venetoclax regimen for improved outcomes in older AML patients, indicating promising efficacy.

Key Points

The study aims to evaluate the efficacy of a regimen combining cladribine, cytarabine, and venetoclax in older or unfit patients with newly diagnosed acute myeloid leukemia.
Phase II clinical trial involving 190 older patients with newly diagnosed AML
Patients received cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax
Trial registered under ClinicalTrials.gov identifier: NCT03586609.
Complete remission rates were 84% and 75% for CR/CRi and MRD negative CR/CRi overall.
Median overall survival was 52 months, with 2- and 5-year OS rates of 60% and 45% respectively.
Among responders, 44% proceeded to allogeneic hematopoietic stem cell transplantation.

Cite This Study

Kadia et al. (2026) studied this question.

synapsesocial.com/papers/69eefd9bfede9185760d449b https://doi.org/10.1002/ajh.70328

View Full Paper

Ask AI

Bookmark

Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider